KK
TVTX icon

KLP Kapitalforvaltning’s Travere Therapeutics TVTX Stock Holding History

KLP Kapitalforvaltning’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
21,000
+2,200
+12% +$97.5K ﹤0.01% 1026
2026
Q1 		$559K Buy
18,800
+800
+4% +$23.9K ﹤0.01% 1378
2025
Q4 		$688K Sell
18,000
-1,500
-8% -$48.8K ﹤0.01% 1245
2025
Q3 		$466K Hold
19,500
– – ﹤0.01% 1436
2025
Q2 		$289K Buy
19,500
+4,500
+30% +$74.6K ﹤0.01% 1615
2025
Q1 		$269K Hold
15,000
– – ﹤0.01% 1614
2024
Q4 		$261K Buy
+15,000
New +$265K ﹤0.01% 1705

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KLP Kapitalforvaltning's TVTX Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Travere Therapeutics (TVTX) stake by 12% in Q2 2026, buying an estimated $97.5K and bringing the position to 21,000 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1026.

KLP Kapitalforvaltning first reported a position in TVTX in Q4 2024 and has held it in 7 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • KLP Kapitalforvaltning held 21,000 shares of Travere Therapeutics worth $1.19M as of Q2 2026.
  • KLP Kapitalforvaltning bought 2,200 Travere Therapeutics shares in Q2 2026, an estimated $97.5K.
  • Travere Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1026 holding.
  • KLP Kapitalforvaltning first reported a position in Travere Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.